Goldman Sachs & Co. LLC, BofA Merrill Lynch,
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio's gene therapy clinical programs include its Lenti-D™
product candidate, currently in a Phase 2/3 study, called the Starbeam
Study, for the treatment of cerebral adrenoleukodystrophy, and its
LentiGlobin® product candidate, currently in five clinical
studies for the treatment of transfusion-dependent β-thalassemia, also
known as β-thalassemia major, and severe sickle cell disease. bluebird
bio's oncology pipeline is built upon the company's leadership in
lentiviral gene delivery and T cell engineering, with a focus on
developing novel T cell-based immunotherapies, including chimeric
antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird
bio's lead oncology programs, bb2121 and bb21217, are anti-BCMA CAR T
programs partnered with Celgene. bb2121 and bb21217 are each currently
being studied in Phase 1 trials for the treatment of relapsed/refractory
multiple myeloma. bluebird bio also has discovery research programs
utilizing megaTALs/homing endonuclease gene editing technologies with
the potential for use across the company's pipeline.
bluebird bio has operations in
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the anticipated final terms, timing and completion
of the proposed offering, and bluebird bio’s existing product candidates
and research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related to
the proposed public offering, that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk of cessation or delay of any of the ongoing or planned
clinical studies and/or our development of our product candidates, the
risk of a delay in the enrollment of patients in our clinical studies,
the risks that the changes we have made in the LentiGlobin drug product
manufacturing process or the HGB-206 clinical study protocol will not
result in improved patient outcomes, risks that the current or planned
clinical studies of the LentiGlobin drug product will be insufficient to
support regulatory submissions or marketing approval in the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171211006139/en/
Source: bluebird bio, Inc.
Investor Relations and Media
bluebird bio, Inc.
Elizabeth
Pingpank, 617-914-8736
epingpank@bluebirdbio.com